Results 191 to 200 of about 46,312 (227)
Some of the next articles are maybe not open access.
The Lancet Haematology, 2020
BACKGROUND Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism.
J. Halton +18 more
semanticscholar +1 more source
BACKGROUND Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism.
J. Halton +18 more
semanticscholar +1 more source
Drugs, 2008
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire +2 more sources
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Mark, Sanford, Greg L, Plosker
openaire +2 more sources
2023
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
International Journal of Stroke, 2020
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source
The Lancet, 2018
BACKGROUND Myocardial injury after non-cardiac surgery (MINS) increases the risk of cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran prevents perioperative venous thromboembolism, but whether this drug can prevent
P. Devereaux +239 more
semanticscholar +1 more source
BACKGROUND Myocardial injury after non-cardiac surgery (MINS) increases the risk of cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran prevents perioperative venous thromboembolism, but whether this drug can prevent
P. Devereaux +239 more
semanticscholar +1 more source
Annals of Internal Medicine, 2020
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau +9 more
semanticscholar +1 more source
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau +9 more
semanticscholar +1 more source
Journal of Gastroenterology and Hepatology, 2020
Anticoagulants play an important role in the management of Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting oral anticoagulants—dabigatran, among patients with Budd–Chiari syndrome.
Sanchit Sharma +4 more
semanticscholar +1 more source
Anticoagulants play an important role in the management of Budd–Chiari syndrome. There is a paucity of data on the efficacy and safety of direct‐acting oral anticoagulants—dabigatran, among patients with Budd–Chiari syndrome.
Sanchit Sharma +4 more
semanticscholar +1 more source
Dabigatran-Induced Esophagitis
Clinical Gastroenterology and Hepatology, 2014We report 2 cases of drug-induced esophagitis associated with dabigatran, a new oral anticoagulant. Both patients were prescribed dabigatran at 110 mg twice daily for atrial fibrillation as an alternative to warfarin. The first case was a 70-year-old man who had been taking dabigatran for 14 days and was referred to our hospital because of retrosternal
Akifumi, Ootani +2 more
openaire +2 more sources
Drug Metabolism and Personalized Therapy, 2020
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
D. Sychev +13 more
semanticscholar +1 more source
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD).
D. Sychev +13 more
semanticscholar +1 more source
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke, 2020Supplemental Digital Content is available in the text. Background and Purpose— Reversal of dabigatran before intravenous thrombolysis in patients with acute ischemic stroke has been well described using alteplase but experience with intravenous ...
J. Beharry +8 more
semanticscholar +1 more source